IRadimed Co. (NASDAQ:IRMD) CEO Roger E. Susi Sells 10,000 Shares

IRadimed Co. (NASDAQ:IRMD) CEO Roger E. Susi sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 23rd. The shares were sold at an average price of $40.31, for a total transaction of $403,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of IRMD stock opened at $43.00 on Thursday. The firm’s 50 day moving average price is $36.45 and its 200-day moving average price is $33.38. IRadimed Co. has a one year low of $21.65 and a one year high of $45.01. The firm has a market cap of $530.71 million, a P/E ratio of 89.58 and a beta of 0.90.

IRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Thursday, October 28th. The medical equipment provider reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. IRadimed had a net margin of 15.77% and a return on equity of 9.44%. During the same period last year, the company posted $0.09 EPS. Analysts forecast that IRadimed Co. will post 0.62 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in IRMD. Captrust Financial Advisors purchased a new stake in IRadimed during the 3rd quarter worth approximately $28,000. BNP Paribas Arbitrage SA increased its stake in IRadimed by 162.0% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 1,095 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 677 shares during the period. UBS Group AG increased its stake in IRadimed by 46.9% during the 1st quarter. UBS Group AG now owns 1,680 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 536 shares during the period. JFS Wealth Advisors LLC purchased a new stake in IRadimed during the 2nd quarter worth approximately $51,000. Finally, Panagora Asset Management Inc. purchased a new stake in IRadimed during the 2nd quarter worth approximately $170,000. 39.18% of the stock is currently owned by hedge funds and other institutional investors.

IRMD has been the topic of several recent analyst reports. Roth Capital boosted their target price on shares of IRadimed from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, November 2nd. Zacks Investment Research upgraded shares of IRadimed from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Thursday, November 4th. Finally, TheStreet upgraded shares of IRadimed from a “c+” rating to a “b” rating in a report on Friday, July 30th.

About IRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Recommended Story: What is Call Option Volume?

Insider Buying and Selling by Quarter for IRadimed (NASDAQ:IRMD)

Receive News & Ratings for IRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRadimed and related companies with MarketBeat.com's FREE daily email newsletter.